SEC Filing Summary: Corcept Therapeutics Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Corcept Therapeutics Incorporated on March 25, 2026. The report discloses a significant regulatory milestone regarding the company's oncology pipeline.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event rather than financial performance data.
Material Changes
The primary material change reported is the U.S. Food and Drug Administration (FDA) approval of Lifyorli (relacorilant). The approval is for use in combination with nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the FDA approval. The filing incorporates a press release (Exhibit 99.1) for further details. No specific financial guidance, risk factors, or contingencies are detailed within the text of this 8-K.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for Lifyorli (relacorilant).
- Review the full text of the press release (Exhibit 99.1) for details on the approval scope and clinical trial data.
- Assess the potential revenue impact of this new indication on the company's overall financial projections.
- Confirm any regulatory restrictions or post-marketing requirements associated with the FDA approval.